Rate My Professor Shabah Shadli

Shadli's research specializations include cognitive neuropsychology, with a focus on the pathophysiology of anxiety and depressive disorders, their comorbidity, and novel treatments such as off-label ketamine for treatment-resistant cases. She utilizes EEG, fMRI, and blood samples to identify response biomarkers for ketamine's mechanism of action. Key publications during her Otago tenure include "Ketamine Effects on EEG during Therapy of Treatment-Resistant Generalised Anxiety and Social Anxiety" (International Journal of Neuropsychopharmacology, 2018), "Generalisation from an auditory to a visual stimulus" (Biological Psychology, 2016), "Frontal localisation of a theory-based anxiety disorder biomarker" (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015), "Trait depressivity prediction with EEG signals via LSBoost" (2021), "Right Frontal Theta: Is It a Response Biomarker for Antidepressants?" (Frontiers in Neuroscience, 2022), "Ketamine for treatment-resistant major depressive disorder" (Journal of Psychopharmacology, 2024), "Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled randomised crossover study" (2024), "Ketamine for treatment-resistant post-traumatic stress disorder" (BJPsych Open, 2025), and "Six weeks open-label oral ketamine for patients with treatment-resistant anxiety disorders" (2025). She presented on right frontal anxiolytic-sensitive EEG theta rhythm in the stop-signal task at the 258th Otago Medical School Research Society meeting in 2021, collaborating with departments of Psychological Medicine and Psychology.